Safety and efficacy of remdesivir on treatment of covid -19: A systematic review

Abstract

Background: The coronavirus disease 2019 (COVID- 19) has become a world health crisis. Remdesivir as first officially approved agent for Covid-19 treatment, we performed a systematic review to judge the protection and efficacy of remdesivir in Covid-19 patients.

Method: During this systemic review, search data obtained from various electronic databases like PubMed, medRxiv.org, google scholar and in www.Clinical Trials. gov for ongoing RCTs. A probe strategy was developed for every database without restrictions for language or years considered. We identified 52 articles, among which 24 full text article are chosen, we rejected article which aren’t relevant to the study.

 Results: The foremost important final health outcome and also all the four studies assessed the protection of this drug by measuring overall serious adverse events. No differences in all-cause mortality, SAEs or AEs were seen among the 5-day, 10-day and standard of care arms within the Spinner et al., trial. We agree that the currently available data isn’t sufficiently strong to support its FDA approval, provided that it’s impractical to completely assess the balance of advantages to harm in COVID-19 infected patients.

 Conclusion: The findings provide corroborating evidence of clinical improvement in randomized, placebo controlled trials of remdesivir therapy. Our findings suggest that remdesivir merits extended clinical use and and should even be efficacious among non severe hospitalized COVID-19 patients.